[1] Brenner H,Kloor M,Pox CP.Colorectal cancer[J].Lancet,2014,383(9927):1490-1502.
[2] Chen Q,Liu Z,Cheng L, et al.An analysis of incidence and mortality of colorectal cancer in China,2003~2007[J].China Cancer,2012,21(3):179-182.
[3] Hsieh P,Yamane K.DNA mismatch repair:molecular mechanism,cancer,and ageing[J].Mech Ageing Dev,2008,129(7-8):391-407.
[4] Hewish M,Lord CJ,Martin SA,et al.Mismatch repair deficient colorectal cancer in the era of personalized treatment[J].Nat Rev Clin Oncol,2010,7(4):197-208.
[5] Sinicrope FA.DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer[J].Nat Rev Clin Oncol,2010,7(3):174-177.
[6] Boland GM,Chang GJ,Haynes AB,et al.Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer[J].Cancer,2013,119(8):1593-1601.
[7] 祝利民,沈克平,周浩,等.胃肠安及四藤方对人结肠癌细胞株干细胞CD133+的影响[J].上海交通大学学报(医学版),2016,36(2):161-165.
[8] Taverna P,Liu L,Hanson AJ,et al.Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen[J].Cancer Chemother Pharmacol,2000,46(6):507-516.
[9] Rosen JM,Jordan CT.The increasing complexity of the cancer stem cell paradigm[J].Science,2009,324(5935):1670-1673.
[10] Zeki SS,Graham TA,Wright NA.Stem cells and their implications for colorectal cancer[J].Nat Rev Gastroenterol Hepatol,2011,8(2):90-100.
[11] O'Brien CA,Pollett A,Gallinger S,et al.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice[J].Nature,2007,445(7123):106-110.
[12] Ricci-Vitiani L,Lombardi DG,Pilozzi E,et al.Identification and expansion of human colon-cancer-initiating cells[J].Nature,2006,445(7123):111-115.
[13] Dallas NA,Xia L,Fan F, et al.Chemoresistant colorectal cancer cells,the cancer stem cell phenotype,and increased sensitivity to insulin-like growth factor-I receptor inhibition[J].Cancer Res,2009,69(5):1951-1957.
[14] Ma S,Lee TK,Zheng BJ,et al.CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway[J].Oncogene,2008,27(12):1749-1758.
[15] Yasuda H,Tanaka K,Saigusa S,et al.Elevated CD133,but not VEGF or EGFR,as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer[J].Oncol Rep,2009,22(4):709-717.
[16] Sinicrope FA,Mahoney MR,Smyrk TC, et al.Prognostic impact of deficient DNA mismatch repair in patients with stage Ⅲ colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy[J].J Clin Oncol,2013,31(29):3664- 3672.
[17] Sargent DJ,Marsoni S,Monges G,et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J].J Clin Oncol,2010,28(20):3219-3226.